Fig. 8.

Implication of the AdipoR1/SIRT1/PGC-1α pathway in the anti-inflammatory effects of adiponectin in control (a) and DMD (b) myotubes. Myotubes were transfected with siRNAs against AdipoR1, SIRT1, PGC-1α, or a negative (non-targeting, NT) control. After transfection, cells were challenged with TNFα/IFNγ, while being or not treated with ApN, as described above. mRNA levels of TNFα, IL-17A, IL-6, and CCL28 were normalized to TBP and presented as relative expression compared to control conditions (i.e., NT siRNA without ApN). The results presented herein are means ± SEM; n = 7–10 independent cultures from 3 to 4 different patients for each group. AdipoR1, adiponectin receptor type 1; SIRT1, sirtuin1; PGC-1α, peroxisome proliferator-activated receptor- coactivator-1 alpha. *p < 0.05, **p < 0.01, ***p < 0.001 for the effects of ApN